1. Real‐world impact of anti‐HER2 therapy‐related cardiotoxicity in patients with advanced HER2‐positive breast cancer. Issue 6 (10th August 2020) Authors: Conduit, C.; de Boer, R. H; Lok, S.; Gibbs, P.; Malik, L.; Loh, Z.; Yeo, B.; Greenberg, S.; Devitt, B.; Lombard, J.; Nottage, M.; Collins, I.; Torres, J.; Nolan, M.; Nott, L. Journal: Asia-Pacific journal of clinical oncology Issue: Volume 16:Issue 6(2020) Page Start: 356 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The role of BRAF mutations in primary melanoma growth rate and survival. (13th June 2015) Authors: Mar, V.J.; Liu, W.; Devitt, B.; Wong, S.Q.; Dobrovic, A.; McArthur, G.A.; Wolfe, R.; Kelly, J.W. Journal: British journal of dermatology Issue: Volume 173:Number 1(2015:Jul.) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The role of BRAF mutations in primary melanoma growth rate and survival. (1st July 2015) Authors: Mar, V.J.; Liu, W.; Devitt, B.; Wong, S.Q.; Dobrovic, A.; McArthur, G.A.; Wolfe, R.; Kelly, J.W. Journal: British journal of dermatology Issue: Volume 173:Number 1(2015:Jul.) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Understanding the role of specialist follow up in early breast cancer, a retrospective review. (April 2021) Authors: Siow, Z.R.; Estacio, O.; Howells, E.; Devitt, B. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗